The attorney general of Wyoming has determined that the state will not reclassify marijuana under state law under a federal rescheduling From the Trump administration.

“The Wyoming Legislature has not legalized medical marijuana, adopted a state-licensed medical marijuana regulatory scheme, or agreed to recognize any other state’s medical marijuana licenses,” Attorney General Keith Kautz (R) said Tuesday. “Therefore, making marijuana subject to a state medical marijuana license in Title III of the Wyoming Controlled Substances Act is inconsistent with the police powers previously exercised by the Wyoming Legislature.”

“The question of whether to remove a type of marijuana from Schedule I of the Wyoming Controlled Substances Act is a matter for the Wyoming Legislature and should not be done through the administrative rulemaking process,” he said.

The Legislature, however, previously enacted a law stating that “if a substance is designated, rescheduled, or eliminated as a controlled substance under federal law,” the drug and substance abuse commissioner “must control the substance under this law in the same manner as federal law” within 30 days.

Under state law, the attorney general serves as the drug and substance abuse commissioner and can formally challenge the state’s automatic rescheduling to prevent it from happening, subject to a public hearing, “giving all interested parties an opportunity to be heard.”

Kautz called a hearing in June to consider the issue, and also accepted public comments via email.

“The Commissioner received eight comments by email. Four of the comments expressed support for leaving medical marijuana and marijuana products in Schedule I of the Wyoming Controlled Substances Act. Four of the comments supported leaving medical marijuana and marijuana in Schedule III of the Wyoming Controlled Substances Act. All of the comments, both by email and in person, focused on the important policy considerations surrounding the legalization of marijuana and marijuana products.

According to the Attorney General, “all marijuana products currently approved by the United States Food and Drug Administration are already scheduled under the Federal Controlled Substances Act.” referring to prescription medications such as dronabinol, Cesamet, and Epidiolex. “The Commissioner will continue to appropriately monitor individual substances as they are approved by the United States Food and Drug Administration.”

“After considering all stakeholder comments, the commissioner has determined that all marijuana products, including marijuana subject to the state’s medical marijuana license, will remain in Schedule I of the Wyoming Controlled Substances Act,” Kautz’s announcement reads. “This decision is final unless changed by statute.”

Under an order issued in April by US Attorney General Todd Blanche, marijuana products regulated by a state medical cannabis license were immediately changed from Schedule I to Schedule III of the Controlled Substances Act (CSA). Annex, as well as marijuana products approved by the Food and Drug Administration (FDA).

An an administrative hearing now underway is examining a broader rescheduling of cannabisincluding for recreational products.

In Wyoming, activists have tried unsuccessfully to put it down initiatives to legalize medical cannabis and decriminalize possession of marijuana on the ballot.

State lawmakers have also considered legislation on the issue, but Wyoming remains one of the few states without legal access to medical marijuana.

In 2022, the speaker of the Wyoming House introduced a bipartisan decriminalization bill to remove criminal penalties for possession of small amounts of cannabis and replace the state’s current felony charge with a $100 fine. But that legislation he did not receive a vote Despite the support of top GOP lawmakers.

A bill to legalize and regulate adult cannabis in Wyoming he advanced from a House committee In 2021, but at the end of that session it didn’t move anymore.

A A survey released in 2020 has been found It found that 54 percent of Wyoming residents approve of allowing adults in the state to “legally possess marijuana for personal use.”

Meanwhile, other states without comprehensive medical cannabis programs are also grappling with changes to state marijuana laws that could trigger federal redistricting action.

A The GOP senator from South Carolina, for example, said that “medical marijuana is now legal.” under a trigger law in the state.

In May, the governing bodies The Alabama Department of Public Health voted against federal rescheduling of marijuana after health officials said they need more time to determine how to implement the change at the state level.

Tennessee Governor Bill Lee (R), on the other hand, signed the legislation this session block automatic review that could have legalized medical marijuana Under state law, after federal drug rescheduling.

user photo Carlos Gracia.

Sascha Mielcar, CEO of Canify AG, inspects all the suppliers the company buys from, retesting each batch and discarding anything out of specification. However, cannabis from other companies is reaching German pharmacies that cannot meet these standards. “There is a market in Germany where you wonder how the product got into it,” says Sascha. The certification standards, he believes, are not being strictly applied.

© Canify

“I don’t like the term GMP cleaning, it’s a complex methodology,” says Sascha. His concern is the microbiological purity of what reaches the patients, a product that clears certification abroad and would not survive the same examination in Germany. Canify only sells flowers that are GMP certified, and Sascha would rather turn away business than release something out of spec.

For repair, Canify uses a GMP validated method. “We don’t revel in repairs, but if we do, we do it through a qualified, validated process,” says Sascha. Others in the market use various methods and claim GMP validation, and Sascha is skeptical of the extent of these standards.

From the early days to the international footprint
Canify was among the first movers in the German market. Founded in 2018, obtained GMP certification in 2021 after three years and huge expenses, trading since the end of 2022, imports, processes and releases products from various countries, including Portugal, Canada, Uruguay, Colombia, South Africa, Lesotho, Spain, Denmark and North Macedonia, for its brands and telemedicine and clinical services on its German soil. Its volume grew tenfold in 2024 and fivefold again in 2025, although price compression means revenue has not grown in line with volume. The company has also announced a merger with MG Health, a Lesotho-based grower and manufacturer with GMP I and II certified facilities, a step that Sascha calls Canify vertically integrated on two continents, and what he believes to be the first fully integrated operator of its kind outside of Canada.

© Canify

Cannabis from a bunker in Nato
The manufacturing site has an unusual history. As cannabis was classified as a narcotic, storage regulations were strict, and Canify built its vault inside a former NATO bunker. “It’s a regular piece of real estate, but it’s quite useful,” says Sascha.

© Canify

In terms of product formats, little has changed. Germany remains a compound market where pharmaceuticals are prepared and the main form factor is still dried flower. “We’re using Stone Age form factors, dried flowers,” says Sascha. He doubts whether edibles are legal in Germany and is wary of vaporizers, where the certification covers the device rather than the cartridge, and there are voices calling for the disappearance of these products from the market. Canify is investing in a fully certified device, closer to an inhaler than a vaporizer, designed for precise dosing and high bioavailability. “Germany remains a composite market, the only real way is to work with pharma,” concludes Sascha.

For more information:
Canify AG
canify.com